U.S. Markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
28.80+0.94 (+3.37%)
At close: 4:00PM EDT
People also watch
PDLIINCYVRTXNBIXALKS
  • C
    China Education Resources CHN V
    China Education Resources CHN V
    MYGN on fire today!
  • G
    Gpabade
    Gpabade
    Its strength in strong profitability and efficiency according to stockFA. Expected to pick up momentum.
  • A
    Anonymous
    Anonymous
    "What a long strange trip it's been." MYGN in the upper $20-s is about where the original huge short position was put on. Market share of HCT hasn't crashed (and seems unlikely to, ever), but price erosion is obvious and sure to continue. Company paints a nice picture going forward, but the key growth items NOW are "multivariate" tests (Vectra, Genesight, Prolaris) which have a greater risk of being "bioequivalent-ed" than single-target tests. Looking to the future, the companion diagnostics market is deeply concealed (It's strongly in the interest of drug companies to conceal the usefulness of CDs as long as they can, and if Myriad wants to do collaborative development, secrecy is a sine qua non). We aren't hearing anything about kit-based products.
  • S
    Susan
    Susan

    Thanks for the tip, I did some research and found more information about $MYGN on http://jcharlesassets.com/opiant-pharmaceuticals/?s=MYGN "hhse" Investing trading stocks.

    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.
    jcharlesassets.com
  • a
    ady
    ady
    800 m sales x 6= 4.8 b : 68 m shares = $ 70. that would be fair value. if you think $ 25 is fair, then you see no future. i believe personalized medicine has only started. mygn has been screwed by former management, it only can get better .......
  • Y
    Yahoo Finance Insights
    Yahoo Finance Insights
    MYGN is up 6.19% to 26.60
  • C
    China Education Resources CHN V
    China Education Resources CHN V
    Nice upward movement yesterday longs!
    get shorty....
  • A
    Anonymous
    Anonymous
    New York Times 6/8/17 has an article about the evidence supporting approval of immunotherapy to treat cancer patients with the genetic defects MSI-H and dMMR. Familial MSI-H defect is Lynch syndrome, which MyRisk tests for. Beyond that, I know nothing of interest.
  • T
    Tracy
    Tracy
    Do you think this thing is done selling? Showing us a buy signal now on MYGN? google awesome.stocks - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • P
    Pharmaherooooooo
    Pharmaherooooooo
    buying AXSM at $4 is like buying JAZZ at $1 a few years ago now trading at $151
    (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $90 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$3.90

    Shares Out: 23.5 Million

    Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
  • t
    tiger
    tiger
    nope , nothing mygn can announce at this point will impact the stock. they dont have a clue how to grow the company.
  • M
    Melissa
    Melissa
    The last time MYGN did something like this it blew up. Not sure how awesome.stocks finds all these incredible trade ideas but im happy.
  • J
    Jennifer
    Jennifer

    https://finance.yahoo.com/quote/DRE/community

    DRE Conversations | Duke Realty Corporation Common - Yahoo Finance
    Welcome to largest financial internet forum where people can hold conversations related to stock trading and investing in equities. You can share your opinion and views on various topics from exciting world of finance.
    finance.yahoo.com
  • A
    Anonymous
    Anonymous
    The Prolaris Medicare reimbursement expansion covers exactly the population most likely to be seeking "one more piece of information" in choosing between watchful waiting or more aggressive treatment.
  • A
    Alejandra
    Alejandra
    Is it time to make a move on MYGN? have you guys heard of awe-someSTOCKS. i started receiving their allerts and so far i am happy.
  • C
    China Education Resources CHN V
    China Education Resources CHN V
    A week ago, I called the $23 pps. MYGN is one of the most heavily shorted stocks on the stock exchange. Major short squeeze could push this stock to $28 in no time!
  • t
    tiger
    tiger
    they beat savagely low expectations. stock is clear to trade at $22 or $23. very impressive, not. they dont really have much of a plan do they? hence the flat quarter in q2. in a down market, it could re-test $15.
  • A
    Anonymous
    Anonymous
    Just listened to the CC. Pretty much what was needed, and what would be expected at this stage of playing out a "dumpster year." Didn't notice much about growth initiatives that are definitely there (esp kit-based tests). Lots of fiddly accounting changes. I now expect a pretty good August call with a forecast that sounds slightly optimistic. The plan, of course, is that they hope to beat the optimistic-sounding forecast by ever-increasing amounts. That's what Myriad used to do. and 15+ months after last August's CC, analysts may easily be receptive. I'd like to have a Shareholders' Day sometime in the next year, but nobody's listening.
  • K
    Kimberly
    Kimberly
    My guess is that MYGN is due for a pullback in the short-run. I started receiving notifications from aawesomestocks the other week and so far they have presented interesting new trade ideas.
  • A
    Anonymous
    Anonymous
    It appears that the PARP inhibitor Rubraca (available now under acccelerated approval) will have a need for BRCA testing on label. The manufacturer is specifying Incyte's test for germ-line mutation, and the drug has been added to Myriad's FDA filings for somatic BRCA mutation testing.

    It's complicated, but it's good news.